ClinicalTrials.gg
RecruitingNCT07226674MAEVEUpdated Nov 13, 2026

Microbiota Mediated Flavonoid Metabolites for Cognitive Health

An interventional study of Polyphenol Supplement and Placebo Supplement in Cognitive Decline and Cognitive Dysfunction, sponsored by University of Ulster. Recruiting at 1 site in United Kingdom. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Ulster · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 13, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Cognitive Dysfunction with a site in United Kingdom — 37 open to participants now, 54 under way, 7 of them phase 3. Cognitive Dysfunction · United Kingdom.

Planned enrollment
39th of 89
100 · median 70
Started
2026
with 4 others
No phase
51 of 138
15 open now
Primary completion
2027-12
later than 38 of 53 live
Registered
128th of 138
by date

Among the 138 studies in Cognitive Dysfunction with a site in United Kingdom, this one is the 39th largest by planned enrollment of the 89 interventional ones that give a count, is one of 5 that started in 2026, is one of 51 with no phase, reaches primary completion later than 38 of the 53 other live ones, and was the 128th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

37 of the 138 studies in Cognitive Dysfunction with a site in United Kingdom are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Cognitive Dysfunction with a site in United Kingdom, or all of them as a file.
02

Study summary

Globally, populations are ageing increasing the prevalence of Alzheimer's disease (AD), due to lack of effective treatments. The traditional Mediterranean diet, rich in fibre and polyphenols (PPs) can help prevent or delay cognitive dysfunction and preserve healthy brain structure and function. Cognitive decline is inversely associated with higher PP intakes (>421mg/day) i.e., total flavonoids, flavan-3-ols and flavonoid oligomers. The positive brain effects of flavonoid intake are likely mediated in part by gut microbial PP metabolites, consistent with the emerging role of the brain-gut microbiome (BGM) system in neurodegeneration. Our preliminary data indicate that circulating phenyl-γ-valerolactones (PVL), neuroprotective compounds exclusively produced by gut microbiota from flavan-3-ol rich foods18 are associated with delaying cognitive dysfunction. Intake of PPs change gut microbial composition and function, altering the physiology of the host's secondary bile acid (BA) pool through modulation of bacterial 7α-dehydroxylation of de-conjugated primary BAs into secondary BAs. This is noteworthy as 7α-dehydroxylation of BAs does not happen in the brain and because gut microbial BA metabolites have regulatory and signalling functions in the brain. The ratio between certain primary and secondary BAs is also dysregulated in AD with significantly lower serum concentrations of cholic acid (a primary BA) and increased levels of deoxycholic acid (a bacterially produced secondary BA). The increased ratio of cholic acid to deoxycholic acid is correlated with cognitive decline. Increased levels of tyrosine, tryptophan, purine, and tocopherol have also been identified in postmortem AD brains. However, specific pathways and mechanisms underlying these associations are unclear. In this multi-PI application by leaders in the field of BGM interactions, we leverage the collectively (NIH, HSC, SFI) funded Tripartite US-Ireland R\&D Partnership Program to determine the mechanisms involved in PP intake on maintaining healthier cognitive and brain function, as mediated by gut microbiota metabolites of PP and BAs in 50+ year old elderly with enhanced AD risk.

03

Conditions studied

  • Cognitive Decline
  • Cognitive Dysfunction

Keywords

  • Polyphenols
  • Mediterranean Diet
  • Gut Microbiome
  • Alzheimer Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50+ years
  • ≥ 25 kg/m2
  • Enhanced risk of AD - defined as family history of AD, 1st degree family member
  • Habitually consume suboptimal diets such as typical Western diet (i.e., high in animal products, refined carbohydrates and processed food).
  • Subjects capable of and willing to comply with the protocol and to give their written .

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment at time of recruitment into the study, as measured by the Mini Mental Status Exam (, score 25-30), and Clinical Dementia Rating (CDR, score=0) or Everyday Cognition Scale-12 (ECog-12, score\<1.36 included).
  • Pre-existing psychosis or psychiatric conditions.
  • Currently receiving treatment for dementia.
  • History of substance abuse or cerebrovascular events.
  • Heavy use of tobacco (>1/2 pack per day)
  • Any intolerance or allergy documented or suspected to one of the components of the study products.
  • Have taken probiotics or antibiotic therapy within the last 1 month
  • Change in medication use in the last 3 months.
  • Frailty, malnutrition, or food allergy/intolerance requiring special diets will also be excluded.
  • Following any specific diet (vegetarian, vegan, etc.)
  • Body weight at enrolment greater than 400lbs due to weight restrictions on the MRI table.
  • Pregnant, breastfeeding, postpartum for less than 6 months, or unwilling to practice during participation in the study.
  • Unable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, or metallic foreign body, etc.)
  • Chronic pain.
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Having a psychological or linguistic inability to sign the ;
  • Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
  • Subject participating in another biomedical study or participation in another study within the 3 months before entry into this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Polyphenol Supplement

    Juice Plus Essentials, Berry Blend Capsules

    Dietary Supplement: Polyphenol Supplement

  • Placebo comparator
    Placebo Supplement

    Dietary Supplement: Placebo Supplement

Interventions

  • Dietary supplementPolyphenol Supplement

    Juice Plus Essentials, Berry Blend Capsules

  • Dietary supplementPlacebo Supplement

    Micronutrient matched placebo

06

What researchers measure

Primary outcomes

  1. Differences in Polyphenol-derived metabolite concentrations pre, mid, & post intervention - stool

    Measurement of metabolomics via stool specimen.

    Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (month 6), and once at the final 12month appointment (month 12)

  2. Differences in Polyphenol-derived metabolite concentrations pre, mid, & post intervention - blood

    Measurement of metabolomics via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  3. Differences in microbiome levels pre, mid, & post intervention - Stool

    16S RNA sequencing to measure microbiome levels via stool specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  4. Differences in microbiome levels pre & post intervention - Blood

    16S RNA sequencing to measure microbiome levels via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  5. Differences in microbiome levels pre, mid, & post intervention - Stool

    Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  6. Differences in microbiome levels pre, mid, & post intervention - Blood

    Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  7. Differences in Cognitive Measures pre, mid, & post intervention - Executive Function

    Administration of a standardized Stroop Neuro-psychological test; participants ability to correctly identify colours when words are printed in conflicting ink colours.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  8. Differences in Cognitive Measures pre, mid, & post intervention - Executive Function

    Administration of a standardized Trails A \& B; participants ability to connect dots, in order, as quickly as possible.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  9. Differences in Cognitive Measures pre, mid, & post intervention

    The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  10. Differences in Cognitive Measures pre, mid, & post intervention

    Administration of a standardized arithmetic task; participants ability to complete quick mental math.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

Secondary outcomes

  1. Differences in tryptophan-associated metabolite profiles pre, mid, and post intervention - Stool

    Measurement of tryptophan-associate metabolite profiles via stool specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  2. Differences in Bile Acid's (BA's) pre, mid, & post intervention - Stool

    Measurement of BA's via stool specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  3. Differences in Inflammatory markers pre, mid, & post intervention - Blood

    Measurement of inflammatory markers via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  4. Differences in Alzheimer's Disease (AD) markers pre, mid, & post intervention - Blood [Time

    Measurement of AD markers via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).

  5. Anthropometrics - BMI

    Measurement of height(in) and weight(lbs), used to calculate body mass index (BMI)

    Time frame: Measured three times, once at each in-clinic appointment (week 0, month 6, month 12)

  6. Questionnaire Data

    Use of validated surveys to assess ingestive behaviours, social isolation, stress, health, physical activity, etc., self-reported by the participant at home.

    Time frame: Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.

  7. Monthly Questionnaire Data

    Collected once a month for the duration of the study (12months).

    Time frame: Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.

  8. Anthropometrics - waist and hip circumference

    Measurement of waist and hip circumference (cm)

    Time frame: Measured three times, once at each in-clinic appointment (week 0, month 6, & month 12)

  9. Systolic and Diastolic Blood Pressure

    Measurement of the pressure of circulating blood at rest

    Time frame: Measured three times, once at each in-clinic appointment (week 0, month 6, month 12).

Other outcomes

  1. Differences in Multimodal Brain Signatures pre, mid, & post intervention

    Neuroimaging of participants brain via magnetic resonance imaging (MRI) procedure.

    Time frame: Measured thrice, once at baseline (week 0), mid-study (month 6), and final 12month appointment (month 12) visit.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Nov 2025 → Mar 2026 and primary completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 10, 2025
StartActual
Mar 3, 2026was Nov 2025
Primary completionEst.
Dec 20, 2027was Jun 2027
CompletionEst.
Jan 20, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 25, 2025→Mar 3, 2026 (actual)
Nov 13, 2026
Primary completion
Jun 2027→Dec 20, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Nov 25, 2025→Mar 3, 2026 (now actual)
    Primary completion Jun 2027→Dec 20, 2027
    + 2 other changes: identifiers and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226674
Lead sponsor
University of Ulster
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Mar 3, 2026
Primary completion
Dec 20, 2027 (estimated)
Completion
Jan 20, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Chris Gill, PhD
Contact
c.gill@ulster.ac.uk
+44 28 7012 3181
Aoife Caffrey, PhD
Contact
a.caffrey@ulster.ac.uk
+44 (0) 28 701 23401
Chris Gill, PhD
principal investigator · Ulster University, Human Intervention Studies Unit, Coleraine, Co. Londonderry, BT52 1SA, United Kingdom.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion